A Phase 2 interventional study of Imatinib Mesylate in Gastrointestinal Stromal Tumors, sponsored by Novartis Pharmaceuticals. Completed. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2012-05-01.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing imatinib in Gastrointestinal Stromal Tumors — 8 open to participants now, 9 under way, 2 of them phase 3. imatinib · Gastrointestinal Stromal Tumors.
Among the 50 studies testing imatinib in Gastrointestinal Stromal Tumors, this one is the 21st largest by enrollment, is one of 5 that started in 2002, is one of 25 in phase 2, and was the 13th registered.
343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.
Browse Gastrointestinal Stromal Tumors studies →8 of the 50 studies testing imatinib in Gastrointestinal Stromal Tumors are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Kumquat Biosciences Inc. · Sites in United States
Ages 18+
University of California, San Diego · Sites in United States
Ages 18+
Reema A. Patel · Sites in United States
Ages 18+
Asan Medical Center · Sites in Korea, Republic of
Ages 20+
By country, each count listing its studies:
imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 20 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 27 · Phase 3 12 · Phase 4 3
First in 2000; this study’s year is marked. 5 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.
Median enrollment 56 across the 50 interventional studies. Of the 37 that completed or were terminated, 8 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
27 studies in Gastrointestinal Stromal Tumors by Novartis: none open now, none under way, none of them phase 3. Of 26 finished, 14 (54%) have results posted.
Among the 27 studies in Gastrointestinal Stromal Tumors by Novartis, this one is the 14th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2002, is one of 13 in phase 2, and was the 3rd registered.
Novartis’s Gastrointestinal Stromal Tumors studies by the year they started, since 2000.
1 of the studies testing imatinib in Gastrointestinal Stromal Tumors that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07406633Kumquat Biosciences Inc.KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 50 studies testing imatinib in Gastrointestinal Stromal Tumors, from their registry updates:
Among Novartis’s 27 in Gastrointestinal Stromal Tumors:
This tab as a report to print or save as PDF → With an account.
This is a extension study of CSTI571B1201 study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Other protocol-defined inclusion / exclusion criteria may apply.
400 mg once daily
Drug: Imatinib Mesylate
once daily
Also known as: STI571
To study the antineoplastic effect of the investigational drug.
To study the safety and pharmacokinetics of the investigational drug.
No study locations are listed for this record.
The record gives a start of Sep 2002 and a primary completion of Jul 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imatinib
Gastrointestinal Stromal Tumors →